file

Jonathan R. Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Curtis Building, Suite 611A
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. RNA-binding protein hur regulates both mutant and wild-type IDH1 in IDH1-mutated cancer
  2. Host IDO2 gene status influences tumor progression and radiotherapy response in KRAS-driven sporadic pancreatic cancers
  3. Evaluation of post-transcriptional gene regulation in pancreatic cancer cells: Studying RNA binding proteins and their mRNA targets
  4. Cancer of the Pancreas
  5. Molecular profiling of patients with pancreatic cancer: Initial results from the know your tumor initiative
  6. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
  7. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
  8. Complex HuR function in pancreatic cancer cells
  9. STAT5A/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair
  10. Precision medicine based on next-generation sequencing and master controllers
  11. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
  12. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2
  13. Elevated HuR in pancreas promotes a pancreatitis-like inflammatory microenvironment that facilitates tumor development
  14. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis from the International Phase III ESPAC-3 Clinical Trial
  15. RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1α signaling in nucleus pulposus cells
  16. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  17. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
  18. CRISPR knockout of the HuR gene causes a xenograft lethal phenotype
  19. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
  20. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer